Investor Relations
Feb 05, 2019
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes MORE >>
Feb 04, 2019
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes MORE >>
Feb 01, 2019
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer MORE >>
Jan 31, 2019
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator MORE >>

SEC Filing Details

Document Details

Form
Filing Date
Feb 4, 2019
Document Date
Feb 4, 2019
Form Description
Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3
Filing Group
Registration Statements
Company
OPKO Health, Inc.